0000905718-14-000283.txt : 20140522
0000905718-14-000283.hdr.sgml : 20140522
20140522201916
ACCESSION NUMBER: 0000905718-14-000283
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140522
FILED AS OF DATE: 20140522
DATE AS OF CHANGE: 20140522
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGILE THERAPEUTICS INC
CENTRAL INDEX KEY: 0001261249
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 101 POOR FARM ROAD
CITY: PRINCETON
STATE: NJ
ZIP: 08540-1715
BUSINESS PHONE: 609-683-1880
MAIL ADDRESS:
STREET 1: 101 POOR FARM ROAD
CITY: PRINCETON
STATE: NJ
ZIP: 08540-1715
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: INVESTOR AB
CENTRAL INDEX KEY: 0000889232
STATE OF INCORPORATION: V7
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36464
FILM NUMBER: 14865263
BUSINESS ADDRESS:
STREET 1: ARSENALSGATAN 8C
STREET 2: SE-103 32
CITY: STOCKHOLM
STATE: V7
ZIP: 00000
BUSINESS PHONE: 46-8-6142000
MAIL ADDRESS:
STREET 1: ARSENALSGATAN 8C
STREET 2: SE-103 32
CITY: STOCKHOLM
STATE: V7
ZIP: 00000
3
1
agile_form3may2014.xml
OWNERSHIP DOCUMENT
X0206
3
2014-05-22
0
0001261249
AGILE THERAPEUTICS INC
AGRX
0000889232
INVESTOR AB
C/O INVESTOR GROWTH CAPITAL, LLC
ONE ROCKEFELLER PLAZA, SUITE 2801
NEW YORK
NY
10020
0
0
1
0
Series B Preferred Stock
2014-05-22
Common Stock
1950200
I
See Footnotes
Series C Preferred Stock
2014-05-22
Common Stock
424557
I
See Footnotes
Convertible Promissory Notes
2014-05-22
Common Stock
135192
I
See Footnotes
As of May 22, 2014 (the "Effective Date"), certain affiliated entities of Investor AB, a publicly held Swedish company (the "Reporting Person"), hold the securities set forth in Table II above of Agile Therapeutics, Inc., a Delaware corporation (the "Issuer"). As a result of the foregoing, as of the Effective Date, the Reporting Person possesses the sole power to vote and the sole power to direct the disposition of the securities of the Issuer set forth in Table II above.
The Reporting Person's interest in the securities of the Issuer set forth in Table II above reported herein is limited to its pecuniary interest, if any, in such securities.
The Issuer's Series B Preferred Stock is convertible by the Reporting Person at any time on a 1.4-for-1 basis and will automatically convert into shares of Common Stock on a 1.4-for-1 basis upon the closing of the Issuer's initial public offering and has no expiration date.
The Issuer's Series C Preferred Stock is convertible by the Reporting Person at any time on a 1.4-for-1 basis and will automatically convert into shares of Common Stock on a 1.4-for-1 basis upon the closing of the Issuer's initial public offering and has no expiration date.
The Issuer's 8% Convertible Promissory Notes (the "Notes") will automatically convert upon the closing of the Issuer's initial public offering into a number of shares of Common Stock equal to the quotient of the aggregate outstanding principal amount and all accrued and unpaid interest due under the Notes divided by the initial public offering price, which is $6.00 per share of Common Stock.
Investor AB By: /s/ Michael V. Oporto, Authorized Signatory
2014-05-22